JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase. It also displays effective antiviral activity in HCV replicon cells (EC50s: 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively).
CV-1808 is a coronary vasodilator, antihypertensive, and antipsychotic following systemic administration in vivo. CV-1808 is an adenosine A2 receptor agonist.